BioHarvest Sciences Inc. Common Stock BHST
1.75 USD -0.04 (-2.23%)
Nov 11, 2026, 3:38 PM EST
1.75 Day range 1.80
1.37 52-week range 8.30
- YTD
- -66.28%
- 1 year
- -74.56%
News
defenseworld.net BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head Contrast BioHarvest Sciences (NASDAQ: BHST - Get Free Report) and Haleon (NYSE: HLN - Get Free Report) are both consumer staples companies, but which is the better investment? We will compare the two…
defenseworld.net Solesence (NASDAQ:SLSN) versus BioHarvest Sciences (NASDAQ:BHST) Financial Review Solesence (NASDAQ: SLSN - Get Free Report) and BioHarvest Sciences (NASDAQ: BHST - Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will contrast…
defenseworld.net BioHarvest Sciences (NASDAQ:BHST) & Interparfums (NASDAQ:IPAR) Head to Head Analysis BioHarvest Sciences (NASDAQ: BHST - Get Free Report) and Interparfums (NASDAQ: IPAR - Get Free Report) are both consumer staples companies, but which is the better business? We will contrast the two…
benzinga.com BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP…
benzinga.com BioHarvest Sciences Board Authorizes Normal Course Issuer Bid To Repurchase Up To 5% Of Outstanding Common Shares BioHarvest Sciences Inc. (NASDAQ:BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for
benzinga.com Maxim Group Maintains Buy on BioHarvest Sciences, Lowers Price Target to $5 Maxim Group analyst Anthony Vendetti maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $12 to $5.
benzinga.com Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8 Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.- benzinga.com Conference Call:
BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
- benzinga.com BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue…
benzinga.com BioHarvest Sciences Enters Agreement For A Rare, Endangered Fragrance Plant Cell Culture With A UAE-Based Customer; Sees $20M-$30M In 2027-28 Sales This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per…- benzinga.com BioHarvest Sciences Receives $1.4M Grant Approval From Israel Innovation Authority BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority…
- benzinga.com BioHarvest Sciences Expands Its Joint Sweetener Development Program With Tate & Lyle To Include Multiple Plant-Based Sweetener Molecules The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong technical progress to date, as well as Tate & Lyle's ambition to equip food and beverage manufacturers…
- benzinga.com BioHarvest Sciences Affirms FY2026 Sales Guidance of $42.000M-$48.000M vs $44.721M Est BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million to $42.000 million-$48.000 million vs $44.721 million estimate.
benzinga.com BioHarvest Sciences Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $8.500M Miss $8.796M Estimate BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 15.38 percent…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com BioHarvest Sciences' CDMO Division Completes Stage 1 Under Multi-Stage Development Agreement, Establishing Stable Saffron Cell Bank For Potential Nutraceutical And Culinary Applications - CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and…
benzinga.com BioHarvest Sciences' CDMO Division Signs $1.2M Stage 2 Contract As Part Of Multi-Stage Development Program For Rare Scent-Producing Plant Used In Global Fragrance Industry BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that…- benzinga.com BioHarvest Sciences Sees FY2026 Sales $42.000M-$48.000M vs $48.432M Est BioHarvest Sciences (NASDAQ:BHST) sees FY2026 sales of $42.000 million-$48.000 million vs $48.432 million analyst estimate.
- benzinga.com BioHarvest Sciences Inc. - Common Stock Q4 EPS $(0.10), Inline, Sales $9.100M Miss $9.279M Estimate BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 41.18 percent increase over losses of $(0.17)…
- benzinga.com BioHarvest Sciences Announces First Successful Stage 1 Stable Cell Culture Of Scent-Producing Plant With Stage 1 now completed, BioHarvest is ready to advance to Stage 2, where cells stored in a proprietary cell bank will be propagated in liquid medium to generate significant biomass. Once stage 2…
- benzinga.com Earnings Scheduled For March 31, 2026
benzinga.com This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com Roth Capital Initiates Coverage On BioHarvest Sciences with Buy Rating, Announces Price Target of $10 Roth Capital analyst Sean McGowan initiates coverage on BioHarvest Sciences (NASDAQ:BHST) with a Buy rating and announces Price Target of $10.
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com Earnings Scheduled For August 11, 2025
- benzinga.com Earnings Scheduled For May 15, 2025
benzinga.com Earnings Scheduled For March 31, 2025